Search

Displaying results 5031 - 5040 of 8698 in total
  1. Drug

    Noscapine

    go.drugbank.com/drugs/DB06174
    Approved

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP3A Inhibitors
  2. Drug

    Eslicarbazepine

    go.drugbank.com/drugs/DB14575
    Approved

    Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate].

    Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  3. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    Therefore, the broad inhibition of FGFR isoforms may be effective against different types of tumors. … [A257714] While effective, disease progression may occur 6 to 8 months after treatment with currently approved FGFR inhibitors is started, and this effect is usually associated with on-target resistance

  4. Drug

    Talmapimod

    go.drugbank.com/drugs/DB05412
    Investigational

    Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

  5. Drug

    Propentofylline

    go.drugbank.com/drugs/DB06479
    Experimental

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics, Cytochrome P-450 Substrates
  6. Drug

    ALT-2074

    go.drugbank.com/drugs/DB05631
    Investigational

    An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. … BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.

  7. Drug

    Lactose

    go.drugbank.com/drugs/DB04465
    ApprovedInvestigationalWithdrawn

    It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.

  8. Drug

    Landiolol

    go.drugbank.com/drugs/DB12212
    ApprovedInvestigational

    A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity for … [A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  9. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions.

  10. Drug

    Tetraethylammonium

    go.drugbank.com/drugs/DB08837
    Investigational

    Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. … As an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide.